The new talking therapy that can help reduce back pain for up to three years
Academics found the benefits can be seen for up to three years after treatment.
Psychotherapists use various talking therapies to help people to overcome stress, emotional and relationship problems or troublesome habits.
For some, lower back pain will be a single incident which recovers on its own but most people with the condition will suffer long-term problems with unpredictable flare-ups.
Most treatments for the condition have 'small to moderate' effects that do not last for a long period of time, experts said.
The new study, published in the journal Lancet Rheumatology, focused on a type of psychotherapy called cognitive functional therapy (CFT) – a type of psychotherapy to 'address the causal mechanisms' of chronic lower back pain and help to change the way people think about and respond to pain.
An international team of researchers, led by experts in Australia, wanted to examine whether CFT brought long-term benefits for patients with lower back pain.
More than 1,000 patients from Australia with lower back pain were recruited to the study.
A third were given 'usual care', a third were given CFT and the final third were given CFT plus another technique known as biofeedback, which tries to teach a person to control automatic body functions.
People who received 'usual care' were given what their GP surgery recommended or what they chose.
Some 300 people with an average age of 48 continued the study to the three-year follow-up point, split between each of the three groups.
Researchers found that CFT, and CFT and biofeedback, were both more effective than usual care in reducing activity limitation caused by lower back pain.
And they also were more effective for reducing pain intensity at three years.
There were no significant differences among patients who did and did not use biofeedback techniques, prompting researchers to say the use of biofeedback 'did not add to effectiveness'.
'Treatment sessions of CFT produced sustained effects at three years for people with chronic disabling low back pain,' the researchers wrote.
'These long-term effects are novel and provide the opportunity to markedly reduce the effect of chronic back pain if the intervention can be widely implemented.'
They added: 'CFT is the first treatment for chronic disabling low back pain with good evidence of large, long-term effects on disability.
'It offers a high-value, low-risk intervention with long-term benefits for patients with persistent, disabling low back pain.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
an hour ago
- New York Times
As Earth Warms, California Fire Season Is Starting Earlier, Study Finds
California's main wildfire season is starting earlier in the year, and human-caused climate change is a major reason, new research finds. The onset of summertime fire activity in large parts of the state has crept into spring by up to two months since the early 1990s, according to a study published Wednesday in the journal Science Advances. The change has been especially pronounced in the Cascade Range in Northern California, the coastal mountains of Central California and coastal Southern California from Monterey to San Diego. Officials and disaster managers in the state now often speak of fire as a year-round hazard, instead of a seasonal threat. The study rules out two factors that might theoretically be behind the shift: buildups of vegetation and changes in the number of fires ignited, either accidentally or on purpose, by humans. The more important drivers, the researchers found, are the effects of greenhouse warming, including earlier and faster snowmelt and a warmer atmosphere that pulls more moisture out of soil and vegetation. Want all of The Times? Subscribe.
Yahoo
2 hours ago
- Yahoo
Cencora Says Famed GLP-1 Class Products Drive Growth, Boosts Profit Outlook
Cencora, Inc. (NYSE:COR) on Wednesday reported third-quarter 2025 sales increased 8.7% to $80.66 billion, beating the consensus of $80.354 billion. Sales increased due to an 8.5% increase in revenue within the U.S. Healthcare Solutions segment and a 10.5% increase in revenue within the International Healthcare Solutions segment. 'Cencora delivered strong financial results in the third fiscal quarter, driven by our pharmaceutical-centric strategy and focus on our growth priorities,' said Robert Mauch, President and CEO of Cencora.U.S. Healthcare Solutions revenue was $72.9 billion in the third quarter of fiscal 2025, up 8.5% due to overall market growth primarily driven by unit volume growth, including increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class and specialty products to physician practices and health systems. International Healthcare Solutions' revenue was $7.8 billion. The company reported adjusted earnings of $4.00, up 19.8% year over year, beating the consensus of $3.82. Adjusted gross profit reached $2.9 billion, up 20.7%, and adjusted operating income was $1.1 billion, up 20.6%. Outlook Cencora updated its fiscal year 2025 financial guidance to reflect stronger earnings growth in the U.S. Healthcare Solutions segment. Cencora expects adjusted earnings to be $15.85-$16.00 versus prior guidance from $15.70-$15.95 and a consensus of $15.81. View more earnings on COR The company updated its fiscal 2025 sales guidance from $317.37 billion-$323.25 billion to approximately $320.31 billion compared to the consensus of $321.64 billion. The guidance assumes revenue growth of approximately 9% from the previous range of 8%-10%. U.S. Healthcare Solutions segment revenue growth is projected between 9%-10%, compared to the previous range of 9%-11%. International Healthcare Solutions segment revenue growth is projected to be in the range of 6%-7% from the previous range of 3% to 4%. Adjusted consolidated operating income growth to be between 15%-16%, from the previous range of 13.5%-15.5%. During the earnings conference call, Cencora said it's too early to assess the impact of Most Favored Nation (MFN) and other policy changes. Cencora's business has not been significantly affected by tariffs, and the company is not changing its sourcing practices as a result. The company remains confident in the stability of its supply chain. The company is monitoring differences in brand versus generic supply chains for risk of shortages and patient access disruptions. Price Action: Cencora stock is trading lower by 2.30% to $285.64 at last check Wednesday. Read Next:Photo by JHVEPhoto via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? CENCORA (COR): Free Stock Analysis Report This article Cencora Says Famed GLP-1 Class Products Drive Growth, Boosts Profit Outlook originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
CBS News
3 hours ago
- CBS News
Endangered fin whale and calf sighting is a "rare occurrence," New England Aquarium scientist says
New England Aquarium researchers recently documented what they say was a rare sighting of an endangered fin whale and its calf. Scientists on a July 24 aerial survey flew over the Northeast Canyons and Seamounts Marine National Monument, about 130 miles southeast of Cape Cod. They observed more than 1,000 marine animals, including seven fin whales, one endangered sperm whale, one humpback whale, two minke whales and more than 900 dolphins. "Seeing an endangered fin whale and its calf is a rare occurrence," assistant research scientist Kate Laemmle said in a statement Wednesday. The aquarium says the 5,000-square-mile monument has four underwater mountains and three deep-sea canyons. On past survey flights, enormous blue whales and other endangered whale species have been spotted in the monument waters. "Each survey speaks to the remarkable array of biodiversity that we see in the Monument," Laemmle said. According to the state's endangered species program, fin whales are the second-largest whale species, growing up to 85 feet long and weighing up to 80 tons. They can venture within 10 miles of the Massachusetts coastline throughout the year. Female whales typically give birth to a single calf off the mid-Atlantic states south between December and April. The fin whale population was once heavily hunted before federal protections, and now the biggest threats to the endangered population are ship strikes and entanglement in fishing gear. The sperm whale is also endangered, with fewer than 6,000 believed to be in the North Atlantic. The species known for its big brain has been seen south of Martha's Vineyard and Nantucket during summer aerial surveys. Earlier this year, researchers installed high-tech buoys in Cape Cod Bay and off Cape Ann to listen for vocalizations from large whales, including the critically endangered North Atlantic right whale.
